MBX Biosciences (MBX) Free Cash Flow (2023 - 2026)

MBX Biosciences has reported Free Cash Flow for 4 years, with the latest figure at -$20.6 million in Q1 2026.

• Quarterly Free Cash Flow rose 10.94% year-over-year to -$20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.4 million (down 14.3% YoY) and the FY2025 annual result came in at -$80.0 million, down 43.96% from the prior year.
• Free Cash Flow fell to -$20.6 million in Q1 2026 per MBX's latest filing, from -$17.2 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$11.0 million in Q1 2024 and troughed at -$23.2 million in Q1 2025.
• A 4-year average of -$16.7 million and a median of -$16.7 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2025 and 2026: Free Cash Flow sank 111.05% in 2025, then climbed 10.94% in 2026.
• Over 4 years, Free Cash Flow stood at -$11.3 million in 2023, then slumped by 43.05% to -$16.1 million in 2024, then retreated by 6.58% to -$17.2 million in 2025, then declined by 20.09% to -$20.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$20.6 million, -$17.2 million, and -$21.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.